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For personal usSummary Background/Objective: Infliximab is regarded as an effective therapeutic to treat
Crohn’s disease. This study aimed to assess the efficacy of infliximab combined with surgery
and to analyze clinical manifestations according to fistula subtypes in patients with fistulizing
perianal Crohn’s disease.
Methods: From April 2013 to December 2015, 47 patients with perianal Crohn’s disease in two
hospitals of South Korea (Goo Hospital, Gangnam Severance Hospital) were evaluated retro-
spectively. Patients were categorized into two groups as simple fistula (n Z 20) and complex
fistula group (nZ 27). All patients received 5 mg/kg of infliximab intravenously at 0, 2, and 6
weeks after surgical treatments. Then every eight weeks, the responders continued to receive
5 mg/kg infliximab for maintenance therapy.
Results: Complete response of induction therapy was 72.3%, and partial response was 27.7%.
After maintenance therapy, complete response was 97.9% and partial response was 2.1%.
There was no patient without a response to infliximab in this study. The median time to thefactor a; CDAI, Crohn’s disease activity index; PDAI, Perianal Crohn’s disease activity index; BMI, Body
IQR, Interquartile range.
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For personalfirst fistula closure was 6.00  8.00 weeks. Infliximab was used on average 2.13  0.71 times
until the first fistula closure. The rate of recurrence was 8.5% and adverse events were 4.2%. In
comparison with clinical manifestations between simple and complex fistula groups, there was
no significant difference except for the coexistence of perianal abscess.
Conclusions: Combined surgical and infliximab therapy was efficacious to treat fistulizing peri-
anal Crohn’s disease with rapid treatment response and favorable clinical outcomes. It is ex-
pected that this top-down strategy with combining surgeries can overcome previous limitations
in treating perianal Crohn’s disease.
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creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Crohn’s disease is a chronic inflammatory condition of the
gastrointestinal tract, which features transmural inflam-
mation predisposing it to fistula formation.1 Although the
cause of Crohn’s disease is unclear, fistula formation of
Crohn’s disease occurs in approximately 17%e50% of pa-
tients.2,3 Especially, perianal fistulas are common mani-
festations of Crohn’s disease with an incidence of 21%e
40%.4e6 Because they tend to increase morbidities as well
as to decrease quality of life, various approaches to treat
fistulizing perianal Crohn’s disease were developed.
Among the therapeutics for Crohn’s disease, infliximab,
a chimeric monoclonal antibody for tumor necrosis factor a
(TNF-a), is regarded as an effective agent to treat fistul-
izing Crohn’s disease. Because it binds to precursors of TNF-
a and neutralize the pro-inflammatory responses, there
were expectations that infliximab can reduce inflammatory
activities and improve healing rates in patients with Crohn’s
disease. Present et al. reported that the rate of complete
response for fistula closure was 46% of the infliximab group,
which was higher than 13% of the placebo group
(PZ 0.001).7 In addition, the ACCENT-II trial demonstrated
that the use of infliximab for maintenance therapy was
effective and safe to treat patients with fistulizing Crohn’s
disease.3 At the 54th week, complete response of the
infliximab maintenance group was 36%, as compared with
19% of the placebo group (P Z 0.009).
In the development of a top-down therapy, infliximab is
considerable as an initial treatment for moderate-to-severe
Crohn’s disease prior to other therapeutics. Especially,
combined surgical and infliximab therapy showed improved
healing rates and reduced recurrent rates in the complex
fistulas.8e10 However, because perianal fistulas are cate-
gorized by various subtypes depending on their locations
and fistula openings, the assessment for treatment
response of infliximab is required in accordance with fistula
subtypes. In addition, the phenotypes and clinical charac-
teristics tend to be different between Eastern and Western
countries. Although the response of the anti-TNF agents in
Asia is expected to be higher than the Western countries,
there is a lack of published reports on the efficacy of
infliximab for perianal Crohn’s disease.11 In these regards,
this study aims to evaluate the efficacy of infliximab com-
bined with surgical procedures in patients with fistulizing
perianal Crohn’s disease in Korea and to analyze the
treatment response according to fistula subtypes.ser (n/a) at KESLI - Yonsei University M
 use only. No other uses without permission2. Methods
2.1. Study population and data collection
From April 2013 to December 2015, patients diagnosed with
perianal Crohn’s disease in two hospitals of South Korea
(Goo Hospital and Gangnam Severance Hospital) were
reviewed retrospectively. Among them, patients who un-
derwent combined surgical and infliximab treatment were
evaluated in this study. Patients who used concomitant
therapeutic agents related with Crohn’s disease were also
included. However, patients who had Crohn’s disease
without perianal involvement, colorectal malignancy,
active tuberculosis, or severe infection were excluded.
Before surgery, all patients were assessed by clinical
examination, colonoscopy, computed tomography, ano-
rectal endoscopic ultrasound and pelvic magnetic reso-
nance imaging to evaluate pathologic lesions and to
determine the types of fistula-in-ano. Perianal fistulas were
classified by intraoperative procedures following Park’s
classification: superficial, intersphincteric, trans-
sphincteric, suprasphincteric, and extrasphincteric fis-
tula.12 Crohn’s disease activity index (CDAI) and perianal
Crohn’s disease activity index (PDAI) were evaluated to
assess the severity of Crohn’s disease. The quantiferon test,
which is used to diagnose tuberculosis, was performed
before using infliximab to prevent the recurrence of
tuberculosis.
Surgical treatments were performed by seton drainage,
fistulotomy, or fistulectomy including incision and drainage.
Fistulotomy was preferred for the low type of fistula
without proctitis. However, seton procedure or fistulec-
tomy were preferred in fistulas with perianal abscess in
complex fistulas. These surgical procedures were deter-
mined by the locations and subtypes of fistulas during the
operation.
After surgery, infliximab was used within postoperative 1
week following the protocol. All patients received inflix-
imab on schedule. This study was approved by the Institu-
tional Review Boards (IRB No. 3-2016-0092).
2.2. Evaluation parameters
The patients were categorized into two types as simple
fistula group and complex fistula group. According to
Park’s classification, patients who had superficial oredical College from ClinicalKey.com by Elsevier on January 24, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
440 E.J. Park et al.intersphincteric fistula were classified as the simple fistula
group. On the other hand, patients who had trans-
sphincteric, suprasphincteric, or extrasphincteric fistulas
were determined as the complex fistula group (Fig. 1).
All patients were evaluated for combined morbidities,
familial or smoking histories, concomitant medications, and
previous history of perianal surgery before using infliximab.
Rectal inflammation was assessed by performing a preop-
erative colonoscopy. Luminal Crohn’s disease, which in-
volves the gastrointestinal tract was evaluated by
preoperative imaging studies and colonoscopy.
The period of Crohn’s disease was calculated by the
duration from the first diagnosis to the last follow-up. The
duration of perianal disease was defined as the time from
receiving the first perianal surgery to the last follow-up.
The existence of concomitant perianal abscess was the
condition that patients had a perianal fistula with perianal
abscess simultaneously. Time to the first fistula closure was
calculated by the period from the first use of infliximab to
the fistula closure. Both CDAI and PDAI were evaluated
before the initial and after the last infusion of infliximab
during the follow-up period. Recurrence was defined when
there was a newly developed fistula in patients with com-
plete or partial response to infliximab. Duration of recur-
rence was calculated by the time between the first fistula
closure and recurrence.
2.3. Definition of treatment response
Treatment response was assessed every visit by clinical
symptoms, physical examination, and imaging studies. ItFigure 1 Study scheme and treatment res
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For personal use only. No other uses without permission. Cwas classified as complete, partial and no response. Com-
plete response was defined as complete closure of fistula
openings without any drainage. Partial response was
defined as reduction of fistula size more than 50 percent
from the baseline including numbers of fistula drainage. All
other clinical results were categorized as no response. The
outcomes of induction therapy were assessed at 10e14
weeks and treatment response of maintenance therapy was
evaluated every 8 weeks.
2.4. Treatment protocol
After surgical treatment of perianal Crohn’s disease, all
patients received induction therapy, in which infliximab at
a dose of 5 mg/kg of body weight is given intravenously at
the intervals of 0, 2, and 6 weeks. Then, the responders of
induction therapy continued to receive infliximab 5 mg/kg
every eight weeks for maintenance therapy. If the patients
had complete response, the use of infliximab was stopped
and changed to azathioprine. In addition, patients who had
partial response continued the maintenance therapy and
assess the treatment response every visit. On the
other hand, patients who had no response discontinued
infliximab.
All surgical procedures were performed before the use
of infliximab. All patients received antibiotics before sur-
gery. After the surgery, seton was removed when the fis-
tulas closed completely. Adverse events related with
infliximab were reported in the electronic charts. Patients
with adverse events discontinued infliximab and altered the
therapeutic agents.ponse classified by Park’s classification.
cal College from ClinicalKey.com by Elsevier on January 24, 2019.
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Table 1 Patient characteristics.
Variables n Z 47
Sex (n, %)
Male 34 (72.3%)
Female 13 (27.7%)
Age (year) 23.5  8.1 (range, 13e48)
10e19 years 16 (34.0%)
20e29 years 24 (51.1%)
30e39 years 3 (6.4%)
 40 years 4 (8.5%)
BMI (kg/m2) 20.8  3.2 (15.2e28.7)
Co-morbidity 3 (6.3%)
Gallbladder stone 1 (2.1%)
Ureteral stone 1 (2.1%)
Old pulmonary tuberculosis 1 (2.1%)
Familial history of Crohn’s
disease
4 (8.5%)
Smoking history 12 (25.5%)
Duration of Crohn’s
disease (year)
2.0  2.6 (0e11)
Duration of perianal
disease (year)
2.1  2.0 (0e8)
Rectal inflammation 34 (72.3%)
Involved GI areas
Ileum (or rectum only) 9 (19.2%)
Ileum þ colon (or rectum) 15 (31.9%)
Ileum þ colon þ rectum 23 (48.9%)
Previous perianal surgery
prior to IFX
None 9 (19.1%)
1 time 15 (31.9%)
2 times 15 (31.9%)
3 times 8 (17.1%)
History of previous perianal surgery
None 10 (21.2%)
Fistulotomy 8 (17.0%)
Seton procedure 18 (38.3%)
Fissurectomy 4 (8.5%)
Incision and drainage 3 (6.4%)
Seton  fistulotomy
(or fissurectomy)
4 (8.5%)
Previous medications
prior to IFX
5-ASA 24 (51.1%)
5-ASA and AZP 10 (21.3%)
5-ASA, AZP, and steroid 1 (2.1%)
5-ASA and steroid 4 (8.5%)
5-ASA and antibiotics 4 (8.5%)
Antibiotics only 3 (6.4%)
Biologics 1 (2.1%)
Preoperative ESR level 18.6  12.8 (2.0e49.0)
Preoperative CRP level 3.9  6.6 (0.1e44.6)
BMI, body mass index; IFX, infliximab; ASA, aminosalicylate;
AZP, azathioprine.
Infliximab for perianal Crohn’s disease 4412.5. Statistical analysis
All statistical data were analyzed using the SPSS program
(Statistical Product and Service Solution 20 for Windows;
SPSS Inc., Chicago, IL), and SAS version 9.2 (SAS Institute,
Cary, NC, USA). Continuous variables were calculated using
the independent t-test or ManneWhitney test. The com-
parison of PDAI before and after use of infliximab was
analyzed by the paired t-test. Categorical variables were
assessed by the chi-square test or Fisher’s exact test. A P
value less than 0.05 was considered statistically significant
in this study.
3. Results
3.1. Patient characteristics
Among a total of 47 patients, the number of males were
higher than the females (72.3% vs. 27.7%). Patients under
30 years old were 85.1%: teenagers (34.0%) and twenties
(51.1%). The average value of body mass index (BMI) was
20.8  3.2 kg/m2 (mean  SD). There were 6.3% of patients
with co-morbidities, and 8.5% with familial history of
Crohn’s disease. In addition, 25.5% of patients had previous
smoking history. The average Crohn’s disease period was
2.0  2.6 years and perianal disease was 2.1  2.0 years.
There were 72.3% of patients with rectal inflammation and
48.9% with luminal Crohn’s disease, which involved the
ileum, colon and rectum simultaneously. Patients who un-
derwent previous perianal surgeries were 82.9%. Seton
drainage was the most common previous surgical proced-
ures (38.3%) among them. 5-aminosalicylates (5-ASA) was
used in 91.5% of patients for Crohn’s medication prior to
using infliximab. There were 2.1% of patients who previ-
ously used biologics (Table 1).
3.2. Clinical manifestations and concomitant
treatments with infliximab
Transsphincteric type was the most common perianal fistula
with 44.7%, and intersphincteric type was the second most
common with 42.6% among the patients. On the other hand,
there were 10.6% of patients with the extrasphincteric type
and 2.1% with the suprasphincteric type. Patients had two
or more fistulas were 57.5%. Perianal abscess was combined
concomitantly in 80.9% and rectovaginal fistula was devel-
oped in 4.3% of patients. The most common concomitant
surgical procedure was seton drainage (72.3%) in this study.
Fistulotomy and fistulectomy were performed in the 10.6%
and 4.3% of patients, respectively. Patients who used 5-ASA
concomitantly combined with both surgical procedures and
infliximab were 80.9% (Table 2).
3.3. Treatment response after combined surgical
and infliximab therapy
The median follow-up period was 11.0  8.0 months
(interquartile range (IQR), 7.0e15.0). The average time to
the first fistula closure was 7.64  4.81 weeks (range, 2e23)
and the median time was 6.00  8.00 weeks (IQR, 5e13). AsDownloaded for Anonymous User (n/a) at KESLI - Yonsei University M
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complex fistula groups had a first fistula closure within 6
weeks. Infliximab was used an average of 2.13  0.71 times
to the first fistula closure. 55.3% of the patients had the first
fistula closure at the second use of infliximab, and 25.5% ofedical College from ClinicalKey.com by Elsevier on January 24, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 2 Clinical manifestations and concomitant treat-
ments with infliximab.
Variables n Z 47
Subtypes of perianal fistulas (n, %)
Intersphincteric 20 (42.6%)
Transsphincteric 21 (44.7%)
Suprasphincteric 1 (2.1%)
Extrasphincteric 5 (10.6%)
Number of fistulas (n,%)
1 20 (42.5%)
2 14 (29.8%)
3 13 (27.7%)
Concomitant perianal abscess 38 (80.9%)
Rectovaginal fistula 2 (4.3%)
Concomitant surgical treatment with IFX
Seton procedure 34 (72.3%)
Fistulotomy 5 (10.6%)
Fistulectomy 4 (8.5%)
Incision and drainage 2 (4.3%)
Seton þ coring out fistulectomy 2 (4.3%)
Concomitant medications with IFX
5-ASA 38 (80.9%)
5-ASA þ AZP 5 (10.6%)
5-ASA þ steroid 2 (4.3%)
5-ASA þ AZP þ steroid 1 (2.1%)
Only antibiotics 1 (2.1%)
IFX, infliximab; ASA, aminosalicylate; AZP, azathioprine.
442 E.J. Park et al.the patients had it at the third time of infliximab use. The
total numbers to use infliximab until the first fistula closure
was 7.96  2.47 times.
After induction therapy, the rate of complete response
was 72.3%, and partial response was 27.7%. After mainte-
nance therapy, complete response was 97.9% and partial
response was 2.1%. There was no patient without a
response to infliximab in this study.
Both CDAI and PDAI values after infliximab therapy were
lower than before infliximab use. The average CDAI wasFigure 2 Time to the
Downloaded for Anonymous User (n/a) at KESLI - Yonsei University Medi
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98.2  26.6 after infliximab uses. The average difference of
PDAI between the before and after infliximab uses was 9.1.
Recurrence of perianal fistula occurred in four patients
(8.5%) and the average time to recurrence was 4.75  2.06
months. The discontinuation of infliximab occurred in one
patient because of psoriasiform dermatitis during mainte-
nance therapy. There were two adverse events: perianal
bleeding and skin eruption (Table 3).3.4. Subanalysis of the response according to fistula
subtypes
As shown in Fig. 1, all patients were categorized as either
the simple or complex fistula group: 20 patients in the
simple fistula group and 27 patients in the complex fistula
group. After induction therapy, 15 patients had complete
response and 5 patients had partial response in the simple
fistula group. On the other hand, there were 19 patients
with complete response and 8 patients with partial
response in the complex fistula group. All patients in simple
fistula group had complete response after maintenance
therapy. However, patients in the complex fistula group had
complete response except for one patient with a partial
response.
According to the treatment response categorized by
Park’s classification, patients with intersphincteric, trans-
sphincteric or suprasphincteric fistulas accomplished com-
plete response in all patients for maintenance therapy
(Fig. 3). However, patients with extrasphinteric fistulas had
40% of complete response in the induction therapy and 80%
of complete response in the maintenance therapy.
The average time to the first fistula closure was not
significantly different between the simple and complex
fistula groups. Infliximab uses of the complex fistula group
were larger than the simple fistula group with marginally
significance (2.30  0.61 vs. 1.90  0.79, P Z 0.077).
Treatment responses in both induction and maintenance
therapy were not significantly different between the simplefirst fistula closure.
cal College from ClinicalKey.com by Elsevier on January 24, 2019.
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Table 3 Treatment response after combined surgeries
with infliximab.
Variables n Z 47
Time to the first fistula closure (week)
Mean  SD (range) 7.64  4.81 (2e23)
Median  IQR (Q1-Q3) 6.00  8.00 (5e13)
Average uses of IFX to the
first fistula closure
2.13  0.71 (1e4)
Detailed uses of IFX to the first fistula closure
1st time 8 (17.0%)
2nd time 26 (55.3%)
3rd time 12 (25.5%)
4th time 1 (2.1%)
Total uses of IFX 7.96  2.47 (3e12)
Response to IFX at induction therapy
Complete response 34 (72.3%)
Partial response 13 (27.7%)
No response 0 (0.0%)
Response to IFX at maintenance therapy
Complete response 46 (97.9%)
Partial response 1 (2.1%)
No response 0 (0.0%)
CDAI
Before IFX injection 208.5  66.5 (85e450)
After IFX injection 98.2  26.6 (50e210)
PDAI
Before IFX injection 12.5  1.9 (9e17)
After IFX injection 3.4  0.8 (2e5)
Recurrence rate 4 (8.5%)
Duration of recurrence,
month
4.75  2.06 (2.0e7.0)
Discontinuation of IFX 1 (2.1%)
Adverse events
Perianal bleeding 1 (2.1%)
Skin eruption 1 (2.1%)
SD, standard deviation; IQR, interquartile; IFX, infliximab; CDAI,
Crohn’s disease activity index; PDAI, perianal Crohn’s disease
activity index.
Infliximab for perianal Crohn’s disease 443and complex fistula groups. Although the PDAI values were
not different between the two groups, PDAI after using
infliximab were decreased more than before using inflix-
imab in both groups (P < 0.001). In addition, patients in the
complex fistula group had higher rates of perianal abscess
than the simple fistula group (96.3% vs. 60.0%, P Z 0.003).
For the surgical treatment, seton drainage was performed
most commonly in the two groups. 5-ASA was most
commonly used with infliximab in both groups. Recurrence
occurred in 5.0% of the simple fistula group and 11.1% of the
complex fistula group. However, there was no statistical
significance in the rate of concomitant surgery and medical
therapies as well as recurrence between the two groups
(Table 4).
4. Discussion
This study was focused to assess the treatment response of
infliximab after combined surgical procedures in patients
with fistulizing perianal Crohn’s disease and to analyzeDownloaded for Anonymous User (n/a) at KESLI - Yonsei University M
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response after using infliximab was more rapid and higher
rates of treatment response than the outcomes of the
ACCENT-II trial.3 The rate of complete response was 72.3%
after induction therapy and 97.9% after maintenance
therapy in this study. In addition, the perianal fistula was
first closed within 6 weeks (median  SD, 6.00  8.00
(range, 5e13)) with an average 2.13 times use of infliximab.
On the other hand, complete response of the ACCENT-II
trial was 55% of patients at 6 weeks after induction ther-
apy and 36% at 54 weeks after maintenance therapy.3,7
Rasul et al. also reported that clinical fistula closure
occurred in 49% of patients at 8 weeks and 46% at 56 weeks
to use infliximab in patients with perianal fistulizing Crohn’s
disease.13 However, it is noticeable that these studies were
performed by using only infliximab without combining sur-
gical procedures. Because surgical procedures such as seton
drainage or fistulectomy has advantages to resolve tissue
inflammation and improve the healing process, a combi-
nation treatment with surgery and infliximab can have
better treatment responses and shorter times of healing
than infliximab or surgery alone.14e18 According to the
comparative analysis by Sciaudone et al., patients who
received combined treatments with infliximab had shorter
times to healing of fistulas and longer times to relapse than
surgery or infliximab alone.15 In addition, a systemic review
and meta-analysis for the treatment of perianal Crohn’s
fistula compared between seton drainage and anti-TNF
agents reported that combined treatments showed signifi-
cantly favorable outcomes in spite of various treatment
responses.19 In these regards, our results can be inter-
preted that a combination therapy with infliximab and
surgery had advantages to treat fistulizing perianal Crohn’s
disease with effective and rapid healing rates.
Perianal fistulas can be classified by subtypes according
to Park’s classification. In this study, we divided patients
into the simple and complex fistula groups because they
can have different healing rates from infliximab according
to locations and complexities of fistula subtypes. Although
the rates of concomitant perianal abscess were higher in
the complex fistula group than the simple fistula group,
treatment responses were not significantly different during
induction and maintenance therapies. In addition, recur-
rence rates, PDAI values, used numbers of infliximab and
periods for the first fistula closure were not significantly
different between the two groups. Because the complex
fistula group is composed of complex fistulas with a high
type such as a suprasphincteric fistula or extrasphincteric
fistula, it can be expected that there are more difficulties
to treat perianal fistulas of the complex fistula group than
the simple fistula group. However, the clinical outcomes of
these two groups were not significantly different as shown
in Table 4. Adequate drainage of perianal abscess, resolving
tissue inflammation and controlling septic conditions from
proper surgical procedures might amplify the effect of
infliximab to close perianal fistulas regardless of their
subtypes. In these aspects, treatment response of inflix-
imab can be comparable among fistula subtypes when sur-
gical treatment is performed properly with infliximab.
Infliximab have been regarded as an alternative therapy
to overcome limitations of conventional treatment for
Crohn’s disease. However, there were concerns for adverseedical College from ClinicalKey.com by Elsevier on January 24, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Figure 3 Treatment response of infliximab combined with surgical procedures according to fistula subtypes.
444 E.J. Park et al.events associated with infliximab. There are various side
effects related with infliximab such as headache, acute or
delayed infusion reaction, leukopenia, serious infection,
antichimeric antibody formation, and increased risk of
malignancy.20 Present et al. reported that headache, ab-
scess formation, upper respiratory tract infection andTable 4 Subanalysis of the response according to fistula subtyp
Simple fistula gr
Time to the first fistula closure (week) 6.80  4.66 (2e
Uses of IFX to the first fistula closure (times) 1.90  0.79 (1e
Response to IFX after induction therapy
Complete response 15 (75.0%)
Partial response 5 (25.0%)
Response to IFX after maintenance therapy
Complete response 20 (100%)
Partial response 0 (0.0%)
PDAI (before IFX) 12.5  1.64 (9.0
PDAI (after IFX) 3.35  0.75 (2.0
Concomitant perianal abscess 12 (60.0%)
Concomitant surgical treatment
Seton procedure 12 (60.0%)
Fistulotomy 4 (20.0%)
Fistulectomy 3 (15.0%)
Incision and drainage 1 (5.0%)
Seton þ coring out fistulectomy 0 (0.0%)
Concomitant CD medication
5-ASA 16 (80.0%)
5-ASA þ AZP 1 (5.0%)
5-ASA þ steroid 2 (10.0%)
5-ASA þ AZP þ steroid 0 (0.0%)
Only antibiotics 1 (5.0%)
Recurrence rate 1 (5.0%)
CD, Crohn’s disease; ASA, aminosalicylate; AZP, azathioprine; IFX, in
a Fisher’s exact test.
b Chi-square test.
c ManneWhitney U test.
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infliximab.7 However, according to the ACCENT-II trial, the
rate of serious adverse events was higher in the placebo
group than the infliximab group (23% vs. 14%, PZ 0.05). In
addition, infection and infusion reaction associated with
infliximab were not significantly different between thees.
oup (n Z 20) Complex fistula group (n Z 27) P value
14) 8.41  4.77 (2e23) 0.234c
3) 2.30  0.61 (1e4) 0.077c
0.726b
19 (70.4%)
8 (29.6%)
1.000a
26 (96.3%)
1 (3.7%)
e17.0) 12.5  2.03 (9.0e17.0) 0.621c
e5.0) 3.37  0.84 (2.0e5.0) 0.963c
26 (96.3%) 0.003a
0.120a
22 (81.5%)
1 (3.7%)
1 (3.7%)
1 (3.7%)
2 (7.4%)
0.198a
22 (81.5%)
4 (14.8%)
0 (0.0%)
1 (3.7%)
0 (0.0%)
3 (11.1%) 0.626a
fliximab; PDAI, perianal Crohn’s disease activity index.
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Table 5 Previous studies with infliximab treatment for perianal Crohn’s fistula.
No Author Year Country Concomitant
therapy
No. of
patients
Follow-up
period
(months)
Response
assessment
Complete
response
(CR)
Partial
response
(PR)
Recurrence
rate
Adverse
event
Before
PDAI
After
PDAI
PDAI P
value
1 Yang et al. 2015 China Surgical &
medical
28 26.4 (14e41) 30th week
(after 6th
injection)
89.3% N/A 7.1% 7.1% 8.54  4.89 0.93  2.08 <0.01
2 Uchino et al. 2011 Japan Surgical &
medical
62
(IFX:n Z 26,
No IFX:n Z 36)
N/A 12the15th
week
0% 88.5% 0%/5yra
53.9%/5yrb
11.3% 11 (8e15) 6 (1e10) <0.01
3 Hukkinen
et al.
2014 Finland Surgical &
medical
13 16 (11e22) 6th week
8th week
23.1%
76.9%
69.2%
15.4%
23.1% 76.9% 35 (26e37) 20 (20e25) N/A
4 Guidi et al. 2008 Italy Surgical &
medical
9 28  16 6th week 88.9% 11.1% 22.2% 11.1% 11.5  2.9 5.4  2.2 <0.01
5 Hyder et al. 2006 UK Surgical &
medical
22 21 (4e31) 6th week 18% 36.4% N/A 0% 11 (8e17) 8 (5e16) <0.01
6 Antakia et al. 2011 UK Surgical &
medical
48 20 8th week 29% 42% 25% 6.3% N/A N/A N/A
7 Topstad et al. 2002 Canada Surgical &
medical
21
(perianal)
10 (3e21) 6th week
(After 3
doses of IFX)
66.7% 19% 19% 24.1% N/A N/A N/A
PCD, perianal Crohn’s disease; IFX, infliximab; PDAI, perianal Crohn’s disease activity index.
a Cumulative incidence of fistula recurrence in patients without anorectal stricture.
b Cumulative incidence of fistula recurrence in patients with anorectal stricture.
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446 E.J. Park et al.infliximab and placebo groups.3 In this study, we had 4.2%
of the patients with side effects, which is a lower rate than
previous studies. Discontinuation during the infliximab
treatment was developed in one patient (2.1%) due to
psoriasiform dermatitis, which can be developed by cuta-
neous eruption from autoimmune disease induced by
infliximab.20,21 There are limitations to assess adverse
events from our small study population. However, because
previous studies with large-scaled long-term outcomes
showed favorable outcomes, it is considered that the use
infliximab is safe and its efficacy might be superior to the
side effects to treat Crohn’s disease.22
The recurrence rate of this study was 8.5% during the
study period. However, the ACCENT-II trial reported that
the loss of response occurred in 42% of patients in the
infliximab maintenance group.3 As shown in Table 5, pre-
vious studies showed various recurrence rates with 7.1%e
55.0%. In the systematic and meta-analysis from Groof
et al., the recurrence rate was reported from 8.0% to
40.9%.19 Because previous studies had different treatment
protocols respectively, the heterogeneity of study designs
tend to make it difficult to assess the recurrence rates.
Although we had a lower rate of recurrence than published
literatures, it is required to assess the recurrence rate
again in the long-term follow-up period.
This study evaluated clinical characteristics of perianal
Crohn’s disease in Korean patients after using infliximab. As
reported by published literatures, there are considerably
different phenotypes and clinical manifestations of Crohn’s
disease between Eastern and Western countries.11,23 Asian
patients with Crohn’s disease tend to be composed of domi-
nantly males with a lower prevalence of cigarette smoking
and familial history. In addition, there are higher proportions
of perianal fistulas in Asian countries than in the West.11,24,25
However, initial treatments using biologics, as called top-
down therapy, are not performed frequently in Asian coun-
tries because of the economic burden on the national insur-
ance system. Burisch et al. reported that biologics were used
7% in Western Europe and 2% in the Eastern as initial treat-
ments during the first 3months of Crohn’s disease.26 Although
it is uncertain that treatment responses of biologics in Asian
patients are more effective than Western, recent studies of
Asian countries showed a rapid response to infliximab and
favorable clinical outcomes. In the reports from China by
Yang et al., 89.3% of patients with perianal fistulizing Crohn’s
disease had complete responses with an average of 31.4 days
healing time.16 Our results also support that infliximab can be
effective to treat fistulizing perianal Crohn’s disease as the
initial treatment. More supportive data in Asian countries are
needed to expand the top-down therapy as the first
treatment.
There are several limitations of this study to assess the
efficacy of infliximab for perianal Crohn’s fistulas. The
small number of the study population has the possibility to
cause type II errors. In addition, because the median
follow-up period of this study was 11.0  8.0 months, it is
needed to assess the rates of recurrence and adverse
events in the long-term period. However, this study is
meaningful because the treatment responses of infliximab
combined with surgical procedures in the Korean patients
with perianal Crohn’s disease were evaluated according to
fistula subtypes. Prospective, randomized controlledDownloaded for Anonymous User (n/a) at KESLI - Yonsei University Medi
For personal use only. No other uses without permission. Cclinical trials for a combined surgical and infliximab treat-
ment are required to support our results in the future.
In conclusion, infliximab combined with surgical pro-
cedures are efficacious and safe to treat fistulizing perianal
Crohn’s disease with rapid and favorable clinical outcomes.
Moreover, treatment response of infliximab can be com-
parable regardless of fistula subtypes when surgical treat-
ment is performed properly with infliximab. Because
recurrence and adverse events occurred limitedly, it is
expected that a combined surgical treatment with inflix-
imab as top-down therapy can overcome the refractory
characteristics of perianal fistulizing Crohn’s disease.Conflict of interest
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